Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and safety in healthy Chinese women from Hong Kong

Hong Kong Medical Journal

Volumn 16, Issue 3, 2010, Pages 171-179

  Ngan, Hextan Y S ^a   Cheung, Annie N Y ^a   Tam, K F ^a   Chan, Karen K L ^a   Tang, H W ^b   Bi, D ^b   Descamps, Dominique ^b   Bock, Hans L ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvants; Cervical intraepithelial neoplasia; Human papillomavirus 16; Human papillomavirus 18; Immunologic; Uterine cervical neoplasms

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID; ALUMINUM HYDROXIDE; CANCER VACCINE; HUMAN PAPILLOMAVIRUS ANTIBODY; IMMUNOLOGICAL ADJUVANT; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHINESE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HONG KONG; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MYALGIA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; SKIN REDNESS; URTICARIA; UTERINE CERVIX CANCER; ADOLESCENT; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HONG KONG; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77955787941     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. American Cancer Society. Global cancer facts and figures. Atlanta: American Cancer Society; 2007.
2. Cervical screening programme, statistics of cervical cancer, Department of Health, The Government of the Hong Kong Special Administrative Region. Hong Kong Department of Health website: http://www.cervicalscreening.gov.hk/english/sr/sr_statistics.html. Accessed 10 Mar 2009.
3. Cervical cancer screening report. Hong Kong Department of Health website: http://www.cervicalscreening.gov.hk/eindex.php. Accessed 19 Mar 2009.
4. Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. Vaccine 2008;26 Suppl 12:M60-70.
5. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007;23:213-27.
6. Bao YP, Li N, Smith JS, Qiao YL; ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008;18:71-9.
7. Muñoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
8. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71.
9. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
10. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26 Suppl 10:K1-16.
11. Lo KW, Wong YF, Chan MK, et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer 2002;100:327-31.
12. Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type-distribution in the cervix of Chinese women: a metaanalysis. Int J STD AIDS 2008;19:106-11.
13. Human papillomavirus vaccines WHO position paper. Wkly Epidemiol Rec 2009;84:118-32.
14. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
15. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
16. Parry J. Vaccinating against cervical cancer. Bull World Health Organ 2007;85:89-90.
17. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008;110(3 Suppl 1):1S-10S.
18. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a populationbased study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:324-7.
19. Carvalho N De, Roteli-Martins C, Teixeira J, et al. Immunogenicity and safety of HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years [abstract]. Proceedings of the 25th International Papillomavirus Conference (IPvC); 2009 May 8-14; Malmo, Sweden.
20. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-49.
21. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet 2006;367:1247-55.
22. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
23. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-7.
24. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 2006;24 Suppl 1:23S-28S.
25. Prevention and screening of cervical cancer, Topical Health Report No. 4, Surveillance and Epidemiology Branch Centre for Health Protection, Department of Health, Government of the Hong Kong Special Administrative Region; 2004.
26. Kwan TT, Chan KK, Yip AM, et al. Barriers and facilitators to human papillomavirus vaccination among Chinese adolescent girls in Hong Kong: a qualitative-quantitative study. Sex Transm Infect 2008;84:227-32.